What was Vivitrol’s (naltrexone for extended-release) market volume in 2024?
No reliable 2024 market-volume figure for Vivitrol is provided in the information available here, and Vivitrol’s 2024 sales can vary depending on what a source counts as “market volume” (units sold, revenue, or prescriptions) and which geography is included.
Where can you find Vivitrol’s 2024 market sales figures?
For drug-level market sales and volume estimates, the most commonly cited sources are:
- Company financial disclosures (if a specific brand is segmented)
- Market research publishers (often paywalled)
- FDA drug utilization/prescription proxies (not always labeled as “market volume”)
If you share the country (U.S. only vs global) and what you mean by “market volume” (revenue in $ vs number of units vs prescriptions), I can help you narrow to the right metric.
Does patent/exclusivity or competition affect how “market volume” is reported?
Vivitrol is a brand of naltrexone extended-release (an injectable). Reported brand market volumes can shift based on:
- Availability of alternative formulations and competing products
- Tendering and payer contracting that change which product patients receive
- Generic or authorized-brand competition (if applicable in the market being measured)
Quick check: should you be looking at “Vivitrol” or another brand name?
Sometimes market trackers group products under active ingredient rather than brand label, which can change “Vivitrol” totals (especially across geographies or time windows). Confirm the geography and measurement method your source uses.
If you want, I can compute/compile a 2024 number—what details do you need?
Reply with:
1) Geography: U.S., EU, or global
2) Metric: revenue ($), units, or prescriptions
3) Time basis: calendar year 2024 or trailing 12 months including part of 2024
With that, I can point you to the correct publicly referenced numbers and sources (including DrugPatentWatch.com where relevant).
Sources
No sources were provided in the prompt for Vivitrol 2024 market volume.